中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系

doi:10.6040/j.issn.1671-7554.0.2016.446

摘要/Abstract

摘要： 目的探讨果蝇zeste增强子同源物2(EZH2)蛋白在中国尤文肉瘤(EWS)患者中的表达与临床病理参数特征及预后的关系。方法收集67例尤文肉瘤/原始神经外胚层肿瘤(EWS/PNET)和其他小圆细胞恶性肿瘤石蜡标本并构建组织芯片,采用荧光原位杂交(FISH)法检测尤文肉瘤断裂位点1(EWSR1)基因易位;应用免疫组织化学法检测肿瘤组织标本中EZH2、Ki-67和P53的表达;应用Kaplan-Meier(K-M)和Cox多因素分析法进行生存分析。结果确诊EWS石蜡组织标本44例;EZH2蛋白在EWS组织中的高表达与肺转移及预后密切相关(P=0.023, P=0.004),并且与Ki-67表达呈正相关性(R=0.406, P=0.006)。EZH2高表达和高Ki-67增殖指数与患者不良预后呈显著相关性(P=0.006, P=0.023);Cox多因素分析表明,P53的表达与EWS患者的总体生存差异无统计学意义(P>0.05),但EZH2和Ki-67是影响患者总体生存的独立预后判定因子(HR=3.467, 95%CI=1.138~10.563, P=0.029; HR=2.140, 95%CI=0.439~10.423, P=0.046)。进一步分析显示,EZH2和Ki-67同时高表达的亚群生存期最短(P=0.012)。结论 EZH2和Ki-67的表达是EWS患者的独立预后因素,并且EZH2和Ki-67的联合检测可以识别预后极差的一部分EWS患者,EZH2可能是EWS新的预后标志物。

关键词: 临床病理学, zeste增强子同源物2, 预后, 免疫组织化学法, 尤文肉瘤, Ki-67

Abstract: Objective To explore the expression of enhancer of zeste homolog 2(EZH2)in Chinese Ewing sarcoma(EWS)patients, and to analyze its correlation with the clinicopathological parameters and prognosis. Methods Tissues from 67 cases of Ewing sarcoma/primitive neuroectodermal tumor(EWS/PNET)and other small round cell malignant tumors were collected and microarrayed. Gene rearrangement in EWS region 1(EWSR1)was evaluated using fluorescence in situ hybridization(FISH). The expressions of EZH2, P53 and Ki-67 were determined using immunohistochemical method. Survival analysis was performed with Kaplan-Meier and Cox method. Results A total of 44 cases were confirmed EWS. EZH2 expression was closely related to lung metastasis(P=0.023)and prognosis(P=0.004)in EWS tissues, and positively correlated to the expression of Ki-67(R=0.406, P=0.006). There was significant correlation between poor prognosis and high expression of EZH2(P=0.06)and high proliferation index of Ki-67(P=0.023). Cox multivariate analysis revealed that there was no significant correlation between P53 expression and overall survival(P>0.05); EZH2 and Ki-67 were independent risk factors for overall survival(HR=3.467, 95%CI=1.138-10.563, P=0.029; HR=2.140, 95%CI=0.439-10.423, P=0.046). In addition, a subset of EWS patients with overexpression of both EZH2 and Ki-67 had the shortest survival time (P=0.012). Conclusion EZH2 and 山东大学学报 (医学版)55卷2期 -张希英,等.中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系 \=-Ki-67 are independent prognostic factors in Chinese EWS patients. A combined detection of EZH2 and Ki-67 can help to identify the subset with extremely poor prognosis. EZH2 may serve as a novel prognostic marker of Ewing sarcoma.

Key words: Ki-67, Ewing sarcoma, Immunohistochemistry, Prognosis, Enhancer of zeste homolog 2, Clinicopathology

中图分类号:

R574

张希英,翟春颜,李劲松,韩博. 中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系[J]. 山东大学学报（医学版）, 2017, 55(2): 84-91.

ZHANG Xiying, ZHAI Chunyan, LI Jingsong, HAN Bo. Expression of EZH2 in Chinese Ewing sarcoma patients and its relationship with clinicopathological parameters and prognosis[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(2): 84-91.

参考文献

[1] Surdez D, Benetkiewicz M, Perrin V, et al. Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth[J]. Cancer Res, 2012, 72(17): 4494-4503.
[2] Borinstein SC, Beeler N, Block JJ, et al. A decade in banking ewing sarcoma: a report from the Childrens oncology group[J]. Front Oncol, 2013, 3: 57. doi:10.3389/fonc.2013.00057.
[3] Paulussen M, Bielack S, Jurgens H, et al. Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up[J]. Ann Oncol, 2009, 20(Suppl 4): 140-142.
[4] Lu C, Han HD, Mangala LS, et al. Regulation of tumor angiogenesis by EZH2[J]. Cancer Cell, 2010, 18(2): 185-197.
[5] Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer[J]. Int J Biol Sci, 2012, 8(1): 59-65.
[6] Tang SH, Huang HS, Wu HU, et al. Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo[J]. Oncotarget, 2014, 5(21): 10342-10355.
[7] Rhodes DR, Sanda MG, Otte AP, et al. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer[J]. J Natl Cancer Inst, 2003, 95(9): 661-668.
[8] Crea F, Hurt EM, Farrar WL. Clinical significance of Polycomb gene expression in brain tumors[J]. Mol cancer, 2010, 9: 265. doi: 10.1186/1476-4598-9-265.
[9] Benard A, Goossens-Beumer IJ, Van Hoesel AQ, et al. Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer[J]. PLoS One, 2014, 9(9): 108265. doi: 10.1371/journal.pone.0108265.
[10] Chen DL, Zhang DS, Lu YX, et al. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer[J]. Oncotarget, 2015, 6(13): 10868-10879.
[11] Liu H, Liu Y, Liu W, et al. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma[J]. Nat Commun, 2015, 6:8494. doi: 10.1038/ncomms 9494.
[12] 刘宝岳, 杨郁, 杜娟, 等. EWS易等位分离探针荧光原位杂交和免疫组织化学抗体(FLI-1和CD99)在尤文肉瘤/原始神经外胚层肿瘤诊断中的价值[J]. 北京大学学报(医学版), 2008, 40(4): 358-362. LIU Baoyue, YANG Yu, DU Juan, et al. Application of the in situ hybridization with EWS dual-color break-apart fluorescence probe and anti-CD99 and anti-FIL-1 antibodies in the diagnosis of Ewing sarcoma/primitive neuroectodermal tumor[J]. Journal of Peking University(Health Sciences), 2008, 40(4): 358-362.
[13] Lin YW, Ren LL, Xiong H, et al. Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer[J]. J Pathol, 2013, 230(3): 277-290.
[14] Zhu Q, Zhang L, Li X, et al. Higher EZH2 expression is associated with extramedullary infiltration in acute myeloid leukemia[J]. Tumour Biol, 2016, 37(8): 11409-11420.
[15] 董玉兰, 杨向红, 高英贤, 等. Ki-67及p53蛋白在口腔鳞状上皮肿瘤中的表达及意义[J]. 中国医科大学学报, 2002, 31(2): 16-17. DONG Yulan, YANG Xianghong, GAO Yingxian, et al. Expression of Ki-67 and p53 in oral squamous epithelial tumor and its significance[J]. J Chin Med Univ, 2002, 31(2): 16-17.
[16] Lu N, Lin T, Wang L, et al. Association of SOX4 regulated by tumor suppressor miR-30a with poor prognosis in low-grade chondrosarcoma[J]. Tumour Biol, 2015, 36(5): 3843-3852.
[17] Tirode F, Laud-Duval K, Prieur A, et al. Mesenchymal stem cell features of Ewing tumors[J]. Cancer Cell, 2007, 11(5): 421-429.
[18] Von Levetzow C, Jiang X, Gwye Y, et al. Modeling initiation of Ewing sarcoma in human neural crest cells[J]. PLoS One, 2011, 6(4): 19305. doi: 10.1371/journal. pone.0019305.
[19] Selvanathan SP, Graham GT, Erkizan HV, et al. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing[J]. PNAS, 2015, 112(11): 1307-1316.
[20] Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life[J]. Nature, 2011, 469(7330): 343-349.
[21] Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex[J]. Mol Cell, 2004, 15(1): 57-67.
[22] Montgomery ND, Yee D, Chen A, et al. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation[J]. Curr Biol, 2005, 15(10): 942-947.
[23] Kim KH, Roberts CW. Targeting EZH2 in cancer[J]. Nat Med, 2016, 22(2): 128-134.
[24] Richter GH, Plehm S, Fasan A, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation[J]. Proc Natl Sci U S A, 2009, 106(13): 5324-5329.
[25] Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets[J]. Cancer Res, 2004, 64(22): 8213-8221.
[26] Riggi N, Suva ML, Suva D, et al. EWS-FLI-1 expression triggers a Ewings sarcoma initiation program in primary human mesenchymal stem cells[J]. Cancer Res, 2008, 68(7): 2176-2185.
[27] Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer[J]. EMBO J, 2003, 22(20): 5323-5335.
[28] Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J]. J Immunol, 1984, 133(4): 1710-1715.
[29] Lopez-Guerrero JA, Machado I, Scotlandi K, et al. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewings sarcoma family of tumors[J]. Int J Cancer, 2011, 128(5): 1139-1150.
[30] Matsukawa Y, Semba S, Kato H, et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer[J]. Cancer Sci, 2006, 97(6): 484-491.
[31] Huqun, Ishikawa R, Zhang J, et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer[J]. Cancer, 2012, 118(6): 1599-1606.

相关文章 15

[1]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[2]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[3]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[4]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[5]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[6]	杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[7]	刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[8]	陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[9]	郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16.
[10]	魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.
[11]	刘春铖,刘晓晗,魏闫若雪,李梓绮,刘玉昆,赵然. 结直肠癌中含溴结构域蛋白9的亚细胞定位模式及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(4): 24-30.
[12]	杨雪彦,吴寅平,吕丽,赵泽华,马行宇,李凤彩,王凯,范玉琛. 单核细胞与淋巴细胞比值动态变化对慢加急性乙型肝炎肝衰竭预后的诊断价值[J]. 山东大学学报 (医学版), 2024, 62(3): 61-69.
[13]	刁玉洁,林琳,李文瑄,王洲洋,江蓓,胡迎迎,刘广义. NPR预测ANCA相关血管炎不良肾脏预后及其协同多因素优化模型[J]. 山东大学学报 (医学版), 2024, 62(2): 60-68.
[14]	吴思雨,沈业隆,王锡明. 影像组学预测原发性中枢神经系统淋巴瘤的Ki-67标记指数[J]. 山东大学学报 (医学版), 2024, 62(11): 67-72.
[15]	宋兆录,董正璇,彭传真,黄彩娜,胡克清,黄永胜,阎磊. 肾透明细胞癌中预后相关RNA编辑位点的筛选[J]. 山东大学学报 (医学版), 2023, 61(9): 69-78.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed